Multiple myeloma: open trials in Norway

33 open trials have a site in Norway. Registry data; only the trial team decides who can take part.

NCT07393282
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Oslo Universitetssykehus HF, Oslo
Registry updated 2026-11-04
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Oslo University Hospital HF, Oslo · St. Olavs hospital HF, Trondheim
Registry updated 2026-11-03
NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Akershus University Hospital, Loerenskog · Oslo Universitetssykehus HF, Oslo · Helse Stavanger HF, Stavanger · St. Olavs hospital HF, Trondheim
Registry updated 2026-11-03
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Oslo University Hospital HF, Oslo
Registry updated 2026-10-29
NCT07735637
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Trial Treatment · Phase 3 · AstraZeneca
Oslo
Registry updated 2026-10-21
NCT06892522
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Trial Treatment · Phase 1/2 · AbbVie
Oslo Universitetssykehus HF, Oslo
Registry updated 2026-10-19
NCT07095452
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Trial Treatment · Phase 2/3 · AbbVie
Oslo Universitetssykehus HF, Oslo
Registry updated 2026-10-19
NCT07878208
Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies
Research · Odense University Hospital
Oslo University Hospital, Oslo
Registry updated 2026-10-16
NCT04643002
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Trial Treatment · Phase 1/2 · Sanofi
Oslo
Registry updated 2026-10-13
NCT06980480
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Trial Treatment · Phase 3 · Takeda
Helse Nord-Trondelag HF, Levanger · Akershus University Hospital, Loerenskog · Oslo Universitetssykehus HF, Oslo · St. Olavs hospital HF, Trondheim
Registry updated 2026-10-13
2026-525367-40-00
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
Trial Treatment · Phase 3 · AstraZeneca AB
Oslo Universitetssykehus HF, Oslo
Registry updated 2026-10-12
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Oslo University Hospital HF, Oslo · St. Olavs hospital HF, Trondheim
Registry updated 2026-10-07
NCT07391657
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Trial Treatment · Phase 3 · AstraZeneca
Oslo
Registry updated 2026-09-29
NCT06988488
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Trial Treatment · Phase 1/2 · Celgene
Oslo University Hospital HF, Oslo · St. Olavs hospital HF, Trondheim
Registry updated 2026-09-02
NCT06285318
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Research · Janssen-Cilag Ltd.
Akershus Universitetssykehus, Oslo · Vestfold Hospital Trust, Tønsberg
Registry updated 2026-08-28
NCT05020236
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Trial Treatment · Phase 3 · Pfizer
Haukeland Universitetssjukehus, Bergen · Oslo University Hospital HF Ullevaal, Oslo · Helse Stavanger HF, Stavanger · St. Olavs hospital HF, Trondheim
Registry updated 2026-08-24
NCT06152575
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Trial Treatment · Phase 3 · Pfizer
Akershus University Hospital, Loerenskog · Oslo University Hospital HF, Oslo · Vestfold Hospital Trust, Tonsberg · St. Olavs hospital HF, Trondheim
Registry updated 2026-08-24
NCT07757412
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
Trial Treatment · Phase 2 · Odense University Hospital
Oslo Universitetssykehus HF, Oslo · Stavanger Univ. Hosp.-Rogaland Hosp., Stavanger · Vestfold Hospital Trust, Tønsberg · St Olavs Hospital, Trondheim
Registry updated 2026-08-11
2025-523285-25-00
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
Trial Treatment · Phase 3 · AstraZeneca AB
Oslo Universitetssykehus HF, Oslo
Registry updated 2026-08-10
2023-505775-70-00
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
Trial Treatment · Phase 2 · European Myeloma Network B.V.
Oslo University Hospital HF, Oslo
Registry updated 2026-08-03
NCT07728188
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · AbbVie
Haukeland University Hospital /ID# 283524, Bergen
Registry updated 2026-07-27
NCT06855121
The Norwegian Immunotherapy in Multiple Myeloma Study
Research · St. Olavs Hospital
Ålesund hospital, Department of hematology, Ålesund · Sørlandet hospital Arendal, Arendal · Bærum Hospital, Bærum · Haukeland University Hospital, Bergen · Bodø Hospital, Bodø · Drammen hospital, Drammen · Førde Hospital, Førde · Innlandet hospital trust, Gjøvik · Haugesund Hospital, Haugesund · Sørlandet hospital, Kristiansand · Nordmøre and Romsdal Hospital - Kristiansund, Kristiansund · Levanger Hospital, Levanger · Nordmøre and Romsdal Hospital - Molde, Molde · Akershus University Hospital (AHUS), Nordbyhagen · Diakonhjemmet Hospital, Oslo · Lovisenberg Diaconal Hospital, Oslo · Oslo Myeloma Center, Oslo University Hospital, Oslo · Telemark Hospital Trust, Skien · Stavanger University Hospital, Stavanger · Vestfold Hospital Trust, Tønsberg · University Hospital of North Norway, Tromsø · St. Olavs hospital HF, Trondheim · Volda hospital, Volda
Registry updated 2026-07-20
NCT06896916
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · AbbVie
Oslo University Hospital HF, Oslo
Registry updated 2026-05-12
NCT06679101
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Trial Treatment · Phase 3 · GlaxoSmithKline
Helse Moere Og Romsdal HF, Aalesund · Helse Bergen HF, Bergen · Akershus University Hospital, Lørenskog · Oslo University Hospital HF, Oslo
Registry updated 2026-04-22
NCT07107529
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Trial Treatment · Phase 2 · European Myeloma Network B.V.
Oslo University Hospital HF, Oslo · Sykehuset I Vestfold HF, Toensberg
Registry updated 2026-04-15

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error